An observational study in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Mario Negri Institute for Pharmacological Research. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Mario Negri Institute for Pharmacological Research · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research — 1 open to participants now, 4 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Mario Negri Institute for Pharmacological Research.
Among the 10 studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 10th registered.
185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.
Browse Polycystic Kidney, Autosomal Dominant studies →1 of the 10 studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research is open now, in 1 country. Recruiting first, the newest first:
Mario Negri Institute for Pharmacological Research · Sites in Italy
Healthy volunteers
By country, each count listing its studies:
Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3
First in 2006; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 45 observational studies indexed under Polycystic Kidney, Autosomal Dominant.
Median enrollment 85 across the 6 interventional studies, 85 across the 4 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mario Negri Institute for Pharmacological Research is the lead sponsor of 161 studies on the registry; 38 are open to participants now.
1 of the studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07016282Mario Negri Institute for Pharmacological ResearchSimulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Polycystic Kidney, Autosomal Dominant by Mario Negri Institute for Pharmacological Research, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a no-profit, retrospective observational study involving real-world data (RWD), retrieved from ADPKD-related electronic health records stored at Mario Negri Institute IRCCS. RWD will be used to generate simulated and synthetic datasets, using AI tools. RWD and generated data (GD) will be used to conduct three virtual RCTs, which main outcome is change in Total Kidney Volume (TKV). Statistical tests will be performed to assess quality and privacy preservation of GD compared with RWD. GD will be also evaluated in exploratory sample size estimations.
Randomized clinical trials (RCTs) can be regarded as the least biased source of information to address intervention questions. One of the most common problems encountered in clinical trials focused on rare diseases is the difficulty in finding patients and therefore in building trials on sufficiently large population, in order to have more robust data and less methodological distortions. Several stratagems are already in use to deal with these problems, including extended trial duration, repeated outcome measures, patients genetic profiles, surrogate endpoint, multicenter studies. Another approach is to consider other trial designs in addition to parallel-arms design, such as crossover trial, n-of-1 trials, and adaptive trials.
Simulated and synthetic health data can represent new valid approaches to increase the representativeness of the patients, especially in rare diseases field, while reducing costs and time constraints, but also facing the limitations imposed by national and international regulations concerning privacy and data management. Simulation studies are defined as computer experiments that involve creating data by pseudo-random sampling from known probability distributions, based on Monte Carlo method. A promising approach now under development includes synthetic data, defined as artificially generated data with the aim of reproducing the statistical properties of an original dataset, through generative large languages models (LLMs).
Thus, while simulated data rely on known distributions that must be specified in advance, synthetic data are generated by LLMs that learn these distributions from training data, without the need for predefined distributions, offering a significant advantage in flexibility and applicability.
This study aims to find the most suitable tool for generating simulated and synthetic data in rare diseases field, and to compare the fidelity, quality, and privacy preservation of these datasets, derived from real-world ADPKD clinical trial data. Furthermore, a virtual clinical trial will be conducted using these three datasets to assess their validity in replicating real trial outcomes.
Finally, retrieved and generated data will be used to assess new sample size estimations for future clinical trial performed at the Clinical Research Center for Rare Disease "Aldo e Cele Daccò", Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica (BG), Italy.
By using generative AI models, such as Generative Adversarial Networks (GANs), this study aims to overcome challenges related to data poverty and trial design. The results could provide valuable insights into whether synthetic data can be a useful tool for improving clinical trials in rare diseases, making them more efficient and cost-effective.
Data from ADPKD patients collected in the form of electronic health records (EHR) stored at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, primarily based on two completed studies performed at the Mario Negri Institue i.e., the ALADIN Study (NCT00309283) and the ALADIN 2 Study (NCT01377246), which enrolled ADPKD-patients treated either with Octreotide-LAR or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Real-world data from ADPKD-related electronic health records (EHR) stored at the Istituto di Ricerche Farmacologiche Mario Negri IRCCS, primarily based on the ALADIN (NCT00309283) and ALADIN 2 (NCT01377246) studies
Data based on RWD from the ADPKD patients and derived from predefined statistical models (e.g., normal distribution for continuous variables, binomial distribution for categorical variables).
Data generated from the RWD of the ADPKD patients using generative large languages models (LLMs)
Changes in total kidney volume (TKV)
Changes in TKV in mL.
Time frame: At baseline, and immediately after data generation procedure.
Plan to share: No
Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polycystic Kidney, Autosomal Dominant →
Mario Negri Institute for Pharmacological Research →